Richter, Allergan amend cariprazine license agreement to include Latin America
Hungarian drugmaker Gedeon Richter on Friday said it amended its existing license agreement with Irish peer Allergan for Richterʼs antipsychotic cariprazine to include major markets in Latin America (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru and Venezuela).
Under the terms of the amended agreement, Allergan will be responsible for the registration of the compound in the newly licensed territories, state news wire MTI reported. Allergan will also pay tiered net sales related royalties to Richter.
"We are very pleased to further increase the geographic coverage of cariprazine for schizophrenia, bipolar I disorder and bipolar depression, providing an innovative treatment for patients suffering from such a complex condition as the spectrum disease," said Richter CEO Gábor Orbán.
Cariprazine was Richterʼs third best-selling drug last year, after contraceptives and the nootropic Cavinton.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.